According to a tobacco control organization, following the World Health Organization's rejection of Medicago's COVID-19 vaccine product Covifenz, Philip Morris International (PMI) has terminated its collaboration with healthcare organization Medicago Inc (a Canadian Quebec-based biopharmaceutical company).
According to Bloomberg, Covifenz, the world's first plant-based COVID-19 vaccine, was developed jointly by Mitsubishi Chemical, Phyto International, and Medicago, owned by GlaxoSmithKline. The Canadian government provided $173 million (approximately RMB 1.2 billion) in funding for its development and has approved its use.
The Quebec government in Canada has announced its intention to assist Medicago, a biotech company, in replacing its shareholder, Phi-Mo International, with another investor. This move will enable the company to distribute its Covifenz COVID-19 vaccine worldwide.
Les Hagen, the Executive Director of non-profit organization ASH Canada, stated in a press release on Monday that "tobacco companies, vaccines, and governments don't mix well, and we support the decision to expel Phibro International from the Medicago partnership.
The World Health Organization has refused Medicago's request for emergency use listing due to its affiliation with the tobacco industry.
Earlier this year, Medicago announced layoffs, with 62 employees being cut from its manufacturing plant in Durham, North Carolina. This facility played a critical role in producing the company's COVID-19 vaccine made from tobacco plants.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
